热门资讯> 正文
Soleno Therapeutics与Oxford Finance达成2亿美元债务融资
2024-12-18 05:12
- Soleno Therapeutics (NASDAQ:SLNO) on Tuesday said it has entered into a loan and security agreement with Oxford Finance and its affiliates for up to $200 million.
- Under the terms of the agreement with Oxford, Soleno drew an initial $50 million at closing and $100 million will be available in three additional tranches, contingent upon U.S. Food and Drug Administration approval of DCCR extended-release tablets for the treatment of Prader-Willi syndrome (PWS) and certain commercial milestones.
- The final $50 million may be made available upon the mutual consent of Soleno and Oxford.
- As of September 30, Soleno had cash, cash equivalents and marketable securities of $284.7M. With the initial draw of $50 million, Soleno had pro-forma cash, cash equivalents and marketable securities of $334.7M as of September 30.
- Source: Press Release
More on Soleno Therapeutics
- Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me
- Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment
- Soleno stock rises as NDA for lead asset doesn’t need FDA advisory meeting
- Seeking Alpha’s Quant Rating on Soleno Therapeutics
推荐文章
华盛早报 | 阿里美股绩后涨近13%，3800亿梭哈AI；美国撤销英特尔等三大芯片巨头在华豁免
港股周报丨外卖"三国杀”！美团跌13%，阿里涨13%；外资大举买入，港股仍具上行动力
一图看懂 | 净利润大幅增长！阿里Q2净利同比增76%至424亿元；闪购业务引流效果显著
一周财经日历 | 大小非农数据来袭，能否决定9月降息计划？蔚来、博通财报压轴登场
一周IPO丨打新“赚钱效应”爆表！佳鑫国际首日飙涨177%；大行科工、劲方医药或即将启动招股
特朗普试图解雇美联储理事库克，美股为何无动于衷？一文解读
自动驾驶成负面资产！调查显示：FSD降低消费者购买特斯拉意愿
还能领先多久？从4月美股触底算起：亚洲科技股持续跑赢纳斯达克100
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
